Procollagen peptide levels in the blood rise with the severity of liver scarring, offering a potential non-invasive alternative to liver biopsy for monitoring fibrosis progression.
p<0.01Procollagen type III N-propeptide was significantly elevated in all schistosomiasis patient groups compared to healthy controls, with levels correlating to fibrosis severity
What the researchers found
Blood levels of procollagen peptides — particularly procollagen type III N-propeptide (PIIINP) — tracked with the severity of liver scarring in both schistosomiasis and alcoholic liver disease. PIIINP was significantly elevated in all schistosomiasis patient groups compared to healthy controls (p<0.01), and patients with worse scarring on biopsy had higher PIIINP levels (p<0.05). In alcoholic patients, PIIINP was even higher and rose with disease severity.
Interestingly, procollagen type I C-propeptide was only elevated during early infection and decreased as disease progressed, suggesting it reflects early-stage collagen production while PIIINP better captures ongoing active fibrosis. Different collagen markers appeared to track different aspects of the scarring process — synthesis versus degradation.
Why it matters
Liver fibrosis progresses silently and conventional liver tests don't reveal how active the scarring process is. Liver biopsy is invasive and only captures a small sample. Blood-based peptide biomarkers like procollagen propeptides could offer a non-invasive way to monitor fibrosis activity in real time — critical for the hundreds of millions of people worldwide with chronic liver disease from various causes.
The numbers in context
n=100 (15 controls + 69 schistosomiasis + 16 alcoholic cirrhosis) · PIIINP elevated p<0.01 · higher histological grade = higher PIIINP p<0.05 · 30 liver biopsies
How the study worked
Cross-sectional study measuring serum concentrations of four collagen-related peptide markers (procollagen type III N-propeptide, procollagen type I C-propeptide, procollagen type IV C-propeptide, and collagen type VI) in healthy controls, three stages of schistosomiasis infection, and alcoholic cirrhosis patients. Correlated with liver biopsy histopathology and collagen histochemistry in 30 schistosomal patients.
Who was studied
15 healthy controls, 69 patients with schistosomiasis (various stages), and 16 patients with alcoholic cirrhosis
What this study cannot tell us
Relatively small sample sizes across groups, especially controls (n=15) and alcoholic cirrhosis (n=16). Cross-sectional design cannot track how biomarker levels change over time in individual patients. The abstract was truncated, so some results regarding collagen type VI and type IV markers are not fully reported. The study is from 1992 and newer fibrosis markers have since been developed.
How to read the evidence
This is an original observational study published in Hepatology with biopsy-correlated biomarker data. While the sample sizes are modest, the direct comparison of blood markers with tissue histology strengthens the findings.
When this study was published
Published in 1992 in Hepatology. This is a foundational study in the development of non-invasive fibrosis biomarkers. While newer and more sophisticated markers are now available, the procollagen peptide approach described here laid essential groundwork and remains part of modern fibrosis panels.
The bigger picture
Non-invasive fibrosis assessment has become one of the most important goals in hepatology. This early 1990s study was part of the wave of research establishing procollagen peptides as fibrosis biomarkers — work that eventually led to today's widely used fibrosis scoring systems (FibroTest, ELF score) that include procollagen markers. Understanding how different collagen peptide fragments reflect different aspects of fibrosis (synthesis vs. degradation, early vs. late stage) has been essential for developing accurate non-invasive monitoring.
Questions still open
- How do procollagen peptide biomarkers compare to newer non-invasive fibrosis tools like FibroScan and the ELF score?
- Can serial procollagen measurements track treatment response in patients receiving anti-fibrotic therapy?
- Do different causes of liver disease produce distinct patterns of collagen peptide biomarker elevation?
Common questions
What are procollagen peptides and why are they in the blood?
Can a blood test replace liver biopsy for detecting fibrosis?
Read the original research
Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease.
Hepatology (Baltimore, Md.), 15(4), 637-44
Citation
Shahin, M; Schuppan, D; Waldherr, R; Risteli, J; Risteli, L; Savolainen, E R; Oesterling, C; Abdel Rahman, H M; el Sahly, A M; Abdel Razek, S M. (1992). Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease.. Hepatology (Baltimore, Md.), 15(4), 637-44.